TY - JOUR
T1 - Dammarane triterpenes targeting α-synuclein
T2 - biological activity and evaluation of binding sites by molecular docking
AU - Cornejo, Alberto
AU - Caballero, Julio
AU - Simirgiotis, Mario
AU - Torres, Vanessa
AU - Sánchez, Luisa
AU - Díaz, Nicolás
AU - Guimaraes, Marcela
AU - Hernández, Marcos
AU - Areche, Carlos
AU - Alfaro, Sergio
AU - Caballero, Leonardo
AU - Melo, Francisco
N1 - Funding Information:
Alberto Cornejo and Carlos Areche acknowledge Instituto Ant?rtico Chileno (INACH) RT_18-19. Julio Caballero acknowledges funds of FONDECYT Regular # 1170718, Mario Simirgiotis FONDECYT Regular # 1180059, and Francisco Melo FONDECYT Regular # 1201013, and Fondequip EQM130149 and USA2055-042031MH_POSTDOC projects are also acknowledged. Vanessa Torres acknowledges APP-1 2019. The authors also thank Daniel Maturana and Carolina Carriel (NanoTemper, Sao Jose dos Campos, Brazil) for help with the thermophoresis assays.
Publisher Copyright:
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Parkinson's disease (PD) is a neurodegenerative disorder that affects adult people whose treatment is palliative. Thus, we decided to test three dammarane triterpenes 1, 1a, 1b, and we determined that 1 and 1a inhibit β-aggregation through thioflavine T rather than 1b. Since compound 1 was most active, we determined the interaction between α-synuclein and 1 at 50 µM (Kd) through microscale thermophoresis. Also, we observed differences in height and diameter of aggregates, and α-synuclein remains unfolded in the presence of 1. Also, aggregates treated with 1 do not provoke neurites' retraction in N2a cells previously induced by retinoic acid. Finally, we studied the potential sites of interaction between 1 with α-synuclein fibrils using molecular modelling. Docking experiments suggest that 1 preferably interact with the site 2 of α-synuclein through hydrogen bonds with residues Y39 and T44.
AB - Parkinson's disease (PD) is a neurodegenerative disorder that affects adult people whose treatment is palliative. Thus, we decided to test three dammarane triterpenes 1, 1a, 1b, and we determined that 1 and 1a inhibit β-aggregation through thioflavine T rather than 1b. Since compound 1 was most active, we determined the interaction between α-synuclein and 1 at 50 µM (Kd) through microscale thermophoresis. Also, we observed differences in height and diameter of aggregates, and α-synuclein remains unfolded in the presence of 1. Also, aggregates treated with 1 do not provoke neurites' retraction in N2a cells previously induced by retinoic acid. Finally, we studied the potential sites of interaction between 1 with α-synuclein fibrils using molecular modelling. Docking experiments suggest that 1 preferably interact with the site 2 of α-synuclein through hydrogen bonds with residues Y39 and T44.
KW - drug target
KW - natural compounds modifiers
KW - oligomers
KW - Parkinson’s disease
UR - http://www.scopus.com/inward/record.url?scp=85097559874&partnerID=8YFLogxK
U2 - 10.1080/14756366.2020.1851216
DO - 10.1080/14756366.2020.1851216
M3 - Article
C2 - 33307873
AN - SCOPUS:85097559874
SN - 1475-6366
VL - 36
SP - 154
EP - 162
JO - Journal of Enzyme Inhibition and Medicinal Chemistry
JF - Journal of Enzyme Inhibition and Medicinal Chemistry
IS - 1
ER -